Participate in Our Study

Trial Condition: Multiple Myeloma


Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma


Trial Purpose

This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring mass accumulation rate (MAR) as a biomarker of patient response to that regimen.

The primary study objective is to explore whether the MAR biomarker can predict patient response in RRMM patients. In order to enable this primary objective, two patient groups will be required. First, a small number of patients with recently diagnosed with multiple myeloma and never treated (Vanguard cohort) will be enrolled to help define drug concentrations used for testing. A second larger group of patients with RRMM will then be enrolled and serve as the primary study cohort. Data will be collected to estimate the biomarker’s predictive properties and to support improvement of the MAR biomarker through additional research and discovery based on the data collected during the study.

Trial Summary


Where to Participate

Title Address Description
Dana Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215, USA
Massachusetts General Hospital
55 Fruit St, Boston, MA 02114, USA
Weill Medical College of Cornell University
407 E 61st St, New York, NY 10065, USA
Icahn School of Medicine at Mount Sinai
1 Gustave L. Levy Pl, New York, NY 10029, USA
Emory University Hospital
1365c Clifton Rd, Atlanta, GA 30322, USA
City of Hope Comprehensive Cancer Center
1500 E Duarte Rd, Duarte, CA 91010, USA
Dana Farber Cancer Institute, Boston MA
Massachusetts General Hospital, Boston MA
Icahn School of Medicine At Mount Sinai, New York, NY
Weill Cornell Medicine - New York Presbyterian, New York, NY
City of Hope Comprehensive Cancer Center, Duarte, CA
Emory University, Atlanta, GA

99A Erie Street Cambridge, MA 02139